Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

PRESS RELEASE Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb Cambridge, UK, September 26 th , 2023 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the milestone. This follows the announcement of the first milestone achieved in the first discovery programme on May 4, 2023.

Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

PRINCETON, N.J.--(BUSINESS WIRE)---- $bmy #bristolmyerssquibb--Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023.

Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023

Following a potential false breakout, Bristol Myers Squibb declined about 27% from its previous all-time high, and the stock might decline further. The company is facing several risks - including political risks like Medicare trying to lower prices or Bristol Myers Squibb struggling to grow (aside from the Celgene acquisition). Even when assuming rather low growth rates, the stock still seems undervalued, and BMY seems like a solid investment.

Bristol Myers Squibb: Undervalued Already, But Could Go Lower

Since Bristol Myers Squibb acquired Celgene for $74 billion in 2019, the stock price has faced challenges and stagnation. The company's defensive strategy to defend the value of its legacy products may not be successful, given impending patent expirations and pricing pressures. BMY envisions a transformation in its revenue composition by 2030, driven by a new product portfolio, but significant changes are unlikely in the next three years.

Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years

BeiGene

Kezar Life Sciences Inc

Novartis

Ocular Therapeutix

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery.

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

Clover Health Investments

Moderna

Healthcare stocks generally offer a lot of upside. The cost of healthcare is incredibly expensive in the United States and the companies that deliver it tend to do very well overall.

Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.

Broadcom

Chevron

Public Service Enterprise Group

Southern Company

TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Chevron and Broadcom.

'Top Wall Street analysts' are bullish on these dividend stocks

Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.

Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Announces Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival.

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer

Subscribers to Schaeffer's Leverage Trader  service more than doubled their investment with our Bristol-Myers Squibb Co  (NYSE:BMY) September 63 put recommendation, all in in just two weeks.

Bearish Bet on Pharma Stock Doubled Investors' Money

INCHEON, South Korea , Sept. 17, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced today a new agreement with Bristol Myers Squibb (NYSE: BMY) for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.

Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance

Pfizer

It's been a rough year to invest in pharma stocks. The industry is adjusting to a sector that is less reliant on Covid-19 vaccines and is adapting to the effects of inflation as well as pressure from regulators to cap the price of many drugs.

The 3 Most Undervalued Pharma Stocks to Buy in September 2023

Bristol Myers Squibb Co. BMY, -0.98% said Thursday that it expects to double the number of drugs in registrational trials over the next 18 months. The pipeline updates, released ahead of the company's research and development day Thursday, include a CD19-directed cell therapy expanding into clinical trials for immunologic diseases, a new cell therapy starting a registrational trial in relapsed/refractory multiple myeloma, and a protein degrader progressing to a Phase 3 trial in first-line large B-cell lymphoma.

Bristol Myers Squibb set to double number of drugs in registrational trials

Bristol Myers Squibb said on Thursday it plans to double the number of treatments it is testing in clinical trials, with a focus on cell therapies, over the next 18 months, as it contends with increasing generic competition for two of its top-selling drugs.

Bristol Myers plans to double experimental treatments to expand research pipeline

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day.

Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day

AbbVie

Top-shelf dividend stocks tend to trade at hefty premiums. Amgen and Bristol Myers Squibb are two clear exceptions to this general rule of thumb.

2 Undervalued Dividend Stocks to Buy Now

Bristol Myers (BMY) posts encouraging data from a phase II study in progressive pulmonary fibrosis.

Bristol Myers' (BMY) Pulmonary Fibrosis Drug Positive in Phase II

Bristol-Myers Squibb Company (NYSE:BMY ) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 8:00 AM ET Company Participants Giovanni Caforio - Chairman of the Board & CEO Christopher Boerner - EVP & COO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Well, thanks.

Bristol-Myers Squibb Company (BMY) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)

Amgen

Cardinal Health

Gilead Sciences

Medtronic

The strong move higher that Nvidia has driven in the stock market this year has been significant, and the world of artificial intelligence has driven stock prices this year.

Big Institutions Grab ‘Strong Buy' Dividend Stocks in a Sector Not Totally Driven by AI

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo Plus Yervoy in the First-Line Treatment.

Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ALOFT--Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study.

Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study

Abbott Labs

Danaher

The pharmaceutical sector will always be a sector in constant evolution and growth. As technology advances, the companies that make life in this sector will always be applying it, as well as implementing new processes, new combinations, and new formulas, always with the aim of being able to make medicines and treatments much more effective and efficient for all of us.

The 3 Best Pharma Stocks to Buy Now: September 2023

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #C2C4C--Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research.

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research

Bristol Myers Squibb has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst for years after it should have faced generic competition.

Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit

AstraZeneca

Johnson & Johnson

Eli Lilly

Merck

The Medicare Modernization Act that established the Part D program in 2003 prohibited the federal government from negotiating drug prices with manufacturers. The Inflation Reduction Act, signed into law by President Biden last year, allows Medicare to start negotiating the prices it will pay for some widely used drugs.

News for Bristol-Myers Stock (BMY)